When is the deal expected to close?

The deal is expected to close in the second half of 2026.

What is the purpose of the acquisition?

Merck aims to strengthen its life sciences and diagnostics portfolio and diversify revenue.

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

Merck KGaA (MRK) announced a $11.3 billion cash acquisition of Bio-Techne Corp, a US biotech firm. The move aims to strengthen Merck's life sciences and diagnostics business.

June 25, 2026

2 min read

Source: Reuters

Key Numbers

deal value

11.3B

Germany's Merck KGaA (MRK) announced on Thursday that it has agreed to acquire US biotech firm Bio-Techne Corp for $11.3 billion in cash. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.

Deal Details

Total Value: $11.3 billion in cash.
Price per Share: Not disclosed.
Premium: Not specified.
Payment Method: All cash.
Timeline: Expected close in H2 2026.

Rationale

Merck aims to bolster its life sciences and diagnostics segment by leveraging Bio-Techne's expertise in biological research tools and reagents. The acquisition also diversifies Merck's revenue streams beyond traditional pharmaceuticals.

Regulatory Challenges

The deal faces antitrust scrutiny in the US and Europe, but analysts expect limited pushback due to minimal business overlap.

Impact on Stocks

Merck's stock (MRK) may face short-term pressure due to the acquisition cost, but long-term growth prospects could improve. Bio-Techne's stock (TECH) is likely to rise on the announcement.

Frequently Asked Questions

The deal is valued at $11.3 billion in cash.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.